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Summary Background Circulating tumor cells (CTCs) and
chemokine (C-X-C motif) receptor 4 (CXCR4) expression in
CTCs and tumor tissue were evaluated as prognostic or pre-
dictive markers of CXCR4 peptide antagonist LY2510924
plus carboplatin-etoposide (CE) versus CE in extensive-
stage disease small cell lung cancer (ED-SCLC). Methods
This exploratory analysis of a phase II study evaluated
CXCR4 expression in baseline tumor tissue and peripheral
blood CTCs and in post-treatment CTCs. Optimum cutoff
values were determined for CTC counts and CXCR4
expression in tumors and CTCs as predictors of survival out-
come. Kaplan-Meier estimates and hazard ratios were used to
determine biomarker prognostic and predictive values. Results
There was weak positive correlation at baseline between
CXCR4 expression in tumor tissue and CTCs. Optimum cut-
off values were H-score ≥ 210 for CXCR4+ tumor, ≥7%CTCs
with CXCR4 expression (CXCR4+ CTCs), and ≥6
CTCs/7.5 mL blood. Baseline H-score for CXCR4+ tumor
was not prognostic of progression-free survival (PFS) or over-
all survival (OS). Baseline CXCR4+ CTCs ≥7%was prognos-
tic of shorter PFS. CTCs ≥6 at baseline and cycle 2, day 1
were prognostic of shorter PFS and OS. None of the bio-
markers at their respective optimum cutoffs was predictive
of treatment response of LY2510924 plus CE versus CE.
Conclusions In patients with ED-SCLC, baseline CXCR4 ex-
pression in tumor tissue was not prognostic of survival or
predictive of LY2510924 treatment response. Baseline
CXCR4+ CTCs ≥7% was prognostic of shorter PFS. CTC
count ≥6 at baseline and after 1 cycle of treatment were prog-
nostic of shorter PFS and OS.
Keywords LY2510924 . CXCR4 expression . Circulating
tumor cells . Small cell lung cancer . Carboplatin-etoposide
Introduction
Small cell lung cancer (SCLC) accounts for approximately
10–15% of all lung cancer cases and is characterized by ag-
gressive growth, early development of metastases, high mor-
tality, and initial response to chemotherapy followed by
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relapse [1]. Approximately 60–70% of patients with
SCLC have extensive-stage disease (ED) [2]. The 5-
year survival rate for patients with SCLC is only 7%
[3]. Patients with ED-SCLC have a median survival of
7–11 months with currently available therapy, and long-
term disease-free survival is rare [4]. Despite develop-
ment of targeted therapies for non-small cell lung cancer
(NSCLC), there have been few advances in treatment
options for patients with SCLC.
To date, no predictive validated biomarker is available for
SCLC outcomes. A meta-analysis showed that elevated che-
mokine (C-X-C motif) receptor 4 (CXCR4) expression corre-
lated with shorter overall survival (OS) in patients with
NSCLC and suggested a poor prognostic outcome of
this disease [5]. The value of CXCR4 expression as a
prognostic marker of SCLC is not known. A lack of
preclinical models or access to patient tissues samples,
as surgery is rarely used to treat SCLC, yields few
tumor specimens for research. Tumor biopsies of
SCLC are difficult to obtain, frequently with low tumor
purity, and the tissue is often necrotic [6]. Repeat biop-
sies are even more problematic, which compounds the
challenges.
Collection of circulating tumor cells (CTCs) permits eval-
uation of biomarkers such as CXCR4 expression in patients
with SCLC, as CTCs are present in high numbers in the pe-
ripheral blood of patients with SCLC [7–9]. This facilitates
using CTCs as a liquid biopsy to examine genetic or
phenotypic markers in patients with SCLC, and provides
an opportunity for repeated sampling during the course
of treatment. In addition to evaluating CXCR4 expres-
sion in CTCs, recent reports have suggested that CTCs
alone may be a useful prognostic or predictive factor for
survival in patients with SCLC, both at baseline and
following 1 or 2 cycles of chemotherapy [10–12].
Cheng et al. [13] reported that, following a second cycle
of treatment, CTCs and change in CTC counts from baseline
were independent indicators for both progression-free survival
(PFS) and OS in patients with ED-SCLC. In a pilot study
analyzing CTCs as a biomarker of chemotherapy response
and relapse, higher baseline CTCs in treatment-naïve patients
with ED-SCLC and the percentage of decrease in post-
treatment CTCs were associated with decreased survival [14].
CXCR4 is implicated in tumor cell motility, survival,
and growth and is often overexpressed in SCLC tumors
and SCLC cell lines [15–17]. CXCR4 activation in
SCLC has been shown to induce migration and invasion
into the extracellular matrix; marrow stromal cells or extracel-
lular matrix proteins may protect SCLC cells from
chemotherapy-induced apoptosis [15, 18, 19], suggesting a
role for CXCR4 in chemotherapy resistance. Stromal cell-
derived factor-1 (SDF-1, C-X-C motif chemokine 12) is an
important ligand of CXCR4 [20].
A phase II study of LY2510924, a novel cyclic peptide that
blocks the binding of the ligand SDF-1 (CXCL12) to CXCR4
[16, 21], was conducted in patients with ED-SCLC who re-
ceived LY2510924 plus carboplatin-etoposide (CE) versus
CE alone (NCT01439568) [22]. There was no difference in
median PFS, the primary efficacy endpoint, between the treat-
ment arms in this study [23], which was approximately
5.9 months in both arms. In exploratory analyses of patients
with ED-SCLC and high CXCR4-expressing tumors at base-
line (H-score ≥ 210), the hazard ratio (HR) for PFS between
the treatment arms was 0.787 (95% confidence interval [CI]:
0.211, 2.933) [24]. Thus, CXCR4 overexpression in SCLC
tumors does not appear to be a predictive biomarker for treat-
ment response to LY2510924 plus CE versus CE alone. Here,
the aim of our post-hoc exploratory analyses was to evaluate
the potential prognostic value of CTC counts and CXCR4
expression in CTCs and in tumor tissue in the overall study
population, and to evaluate potential predictive value of these
biomarkers for treatment with LY2510924 plus CE versus CE
alone. In addition, we evaluated the correlation of baseline
CXCR4 expression in tumor tissue and in CTCs from patients
in this phase II study.
Methods
Patients and treatments
In a phase II study [22], patients with ED-SCLC were ran-
domized 1:1 to receive CE versus LY2510924 plus CE.
Carboplatin (area under the curve [AUC] 5) and etoposide
(100 mg/m2) were administered intravenously on day 1 and
days 1–3, respectively, for up to six 21-day cycles.
LY2510924 (20 mg) was administered subcutaneously daily
on days 1–7 for up to six 21-day cycles. In accordance with
the Declaration of Helsinki, written informed consent was
obtained from all enrolled patients before initiating any study
procedure. The study protocol was approved by an ethics
committee and conformed to principles of Good Clinical
Practice.
Isolation and enumeration of CTCs and detection
of CXCR4 expression
Blood from patients with ED-SCLC was collected into a
CellSave preservative tube (Janssen Diagnostics, Raritan,
NJ) at baseline (day 1 of cycle 1), day 7 of cycle 1, day 1 of
cycle 2, and at 30-day follow-up after the last dose of study
drug. Circulating tumor cells were isolated and enumerated
using the CXC CELLSEARCH® kit and CELLSEARCH®
system according to the manufacturer’s instructions (Janssen
Diagnostics LLC, Raritan, NJ) as previously described [25].
Details of the CTC assay for CXCR4 expression detection are
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provided in Supplementary Materials and Methods. After
CTC enumeration of each sample, CXCR4 expression was
determined by an operator and defined as CXCR4-positive
or -negative by visual phenotyping and classification.
Details of CXCR4 quantification are provided in the
Supplementary Materials and Methods. Representative im-
ages of tumor cell lines expressing varied levels of CXCR4
and a CXCR4+ CTC sample from a patient with SCLC are
shown in Supplementary Fig. S1a–g.
Baseline CXCR4 expression in tumors
by immunohistochemistry
CXCR4 expression analysis was performed on formalin-
fixed, paraffin-embedded tumor tissue. Immunohistochemistry
(IHC) staining for CXCR4 (rabbit anti-human CXCR4 mono-
clonal antibody, clone UMB2; Epitomics Inc., Burlingame, CA)
was performed at Bostwick Laboratories (Uniondale, NY) on an
intelliPATH FLX AutoStainer (Biocare Medical, Concord, CA)
using heat-induced antigen retrieval and standard techniqueswith
3,3′-diaminobenzidine as chromogen and hematoxylin counter-
stain. Stained slides were reviewed by board-certified patholo-
gists; anH-score (0–300) for CXCR4 expressionwas assigned to
each sample. Immunostaining intensity was assessed by visual
assessment: 0 (no staining), 1+ (low intensity), 2+ (intermediate
intensity), and 3+ (strong intensity). H-scores were calculated
from the percentage of cells (in increments of 10%) at different
staining intensities, using the formula: 0 (% of 0 staining cells) +
1 x (%of 1+ staining cells) + 2 x (% of 2+ staining cells) + 3 x (%
of 3+ staining cells).
Statistical analysis methods
A 2-sided significance (alpha) level of 0.05 was used to iden-
tify variables that may be predictive of PFS at 6 months or OS
at 11.5 months. All other statistical testing was 2-sided at
alpha level of 0.10. These analyses were hypotheses-
generating and no adjustments for multiple comparisons were
made; results should be interpreted with caution due to the
possibility of a false positive. All statistical analyses were
performed using SAS® version 9.2.
Biomarkers of CTC counts and CXCR4 expression in tu-
mors and CTCs were summarized for the overall study popu-
lation and by treatment arm. Baseline values were compared
between treatment arms using a Mann-Whitney test. The
Pearson product moment correlation coefficient for baseline
CXCR4 expression in tumor tissue versus CTCs was calcu-
lated. Receiver operating characteristic (ROC) curves, AUCs,
andWald 95%CIs were generated using PROCLOGISTIC to
determine optimum biomarker cutoffs (i.e., values that opti-
mize sensitivity plus specificity). PFS and OS were evaluated
at 4 and 6 months by optimum biomarker cutoffs using
Kaplan-Meier analysis and log-rank test using PROC
LIFETEST, with a Cox proportional hazards regression anal-
ysis using PROC PHREG to determine the HR and corre-
sponding 95% CI.
Results
Patient characteristics and biomarker levels
Patient characteristics and demographics were published pre-
viously [23]. Of the 94 patients randomized, 90 ED-SCLC
patients received treatment with LY2510924 plus CE
(N = 47) or CE (N = 43) and comprised the overall study
population. The present exploratory analyses included data
from the efficacy population of 89 patients (Table 1):
LY2510924 plus CE (N = 47) or CE (N = 42); data from 1
patient in the CE arm were excluded due to sub-therapeutic
dosing on cycle 1, day 1 (protocol violation). The CXCR4
detection assay in CTCs became available after the study
had started, and 25 of 292 samples had CTC counts without
CXCR4 expression evaluation. A total of 15 patient blood
samples did not yield evaluable CTC data due to insufficient
sample volume, interference substance detected in enriched
CTCs, or incorrect sample handling.
There were no statistical differences between treatment
arms for baseline tumor CXCR4 expression, CXCR4 expres-
sion in CTCs, and CTC counts (Table 1). At baseline, 83% of
the overall study population had ≥1 CTCs/7.5 mL blood
with a mean of 851.0 and median of 51.0. The baseline
%CXCR4+ CTCs mean was 23.6 with a median of
18.0. The CXCR4+ tumor tissue H-score mean was
203.0 with a median of 200.0. For the overall study
population, baseline CXCR4 expression in tumor tissue
positively correlated with baseline %CXCR4+ CTCs
(r = 0.423, 95% CI = 0.174, 0.616; P = 0.001)
(Supplementary Table S1; Supplementary Fig. S2a).
Prognostic value of biomarker levels for PFS and OS
The phase II study demonstrated no difference in outcomes
between the 2 treatment arms [23]; therefore, the overall study
population data were combined to determine optimum cutoffs
based on ROC for 6-month PFS (Supplementary Table S2;
Supplementary Fig. S2b–f). These optimum cutoff values
were: H-score ≥ 210 for CXCR4+ tumor tissue, CTCs ≥6/
7.5 mL blood, and CXCR4+ CTCs ≥7%, and were evaluated
by treatment and visit (Supplementary Table S3) or end-
point (Supplementary Table S4). The AUC values for
these 3 optimum cutoffs with sensitivity, specificity,
and positive and negative predictive values are shown
in Supplementary Table S2. Baseline %CXCR4+ CTCs
was the only biomarker with a lower limit of the CI for
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Table 1 Baseline tumor CXCR4
expression by IHC and CTC
counts and CXCR4 expression in
CTCs (%CXCR4+ CTC) at
baseline and post-treatment by
treatment arm or overall study
population
Biomarker LY2510924 + CE
(N = 47)
CE
(N = 42)
Total
(N = 89)
CXCR4+ Tumor Tissue
Baseline
Patients with evaluable results, n 36 33 69
Mean H-score (SD) 205.8 (80.4) 199.8 (85.2) 203.0 (82.2)
Median H-score (range) 200.0 (20, 300) 200.0 (5, 300) 200.0 (5, 300)
P-value* 0.808
CTC Count
Baseline
Patients with evaluable results, n 42 36 78
Mean (SD) 615.5 (1419.4) 1125.7 (3865.7) 851.0 (2816.2)
Median (range) 20.5 (0, 7153) 98.5 (0, 21,428) 51.0 (0, 21,428)
P-value* 0.262
Patients with CTC, n/N (%) 33/42 (78.6) 32/36 (88.9) 65/78 (83.3)
Cycle 1, day 7
Patients with evaluable results, n 32 30 62
Mean (SD) 118.2 (461.3) 57.4 (156.1) 88.8 (347.3)
Median (range) 4.0 (0, 2624) 2.5 (0, 594) 2.5 (0, 2624)
Patients with CTC, n/N (%) 23/32 (71.9) 19/30 (63.3) 42/62 (67.7)
Cycle 2, day 1
Patients with evaluable results, n 34 27 61
Mean (SD) 70.6 (209.3) 25.1 (79.9) 50.5 (165.5)
Median (range) 1.5 (0, 875) 0.0 (0, 406) 0.0 (0, 875)
Patients with CTC, n/N (%) 18/34 (52.9) 12/27 (44.4) 30/61 (49.2)
30-day follow-up
Patients with evaluable results, n 29 25 54
Mean (SD) 128.5 (476.3) 5.2 (18.1) 71.4 (351.9)
Median (range) 0.0 (0, 2008) 0.0 (0, 87) 0.0 (0, 2008)
Patients with CTC, n/N (%) 14/29 (48.3) 9/25 (36.0) 23/54 (42.6)
%CXCR4+ CTCs
Baseline
Patients with evaluable results, n 37 33 70
Mean (SD) 21.0 (26.3) 26.6 (24.7) 23.6 (25.5)
Median (range) 10.9 (0.0, 100.0) 21.1 (0.0, 100.0) 17.8 (0.0, 100.0)
P-value* 0.182
Cycle 1, day 7
Patients with evaluable results, n 29 27 56
Mean (SD) 0.1 (0.2) 9.2 (17.5) 4.4 (12.9)
Median (range) 0.0 (0.0, 1.0) 0.0 (0.0, 58.3) 0.0 (0.0, 58.3)
Cycle 2, day 1
Patients with evaluable results, n 33 24 57
Mean (SD) 7.9 (15.0) 10.6 (19.7) 9.1 (17.0)
Median (range) 0.0 (0.0, 50.0) 0.0 (0.0, 66.6) 0.0 (0.0, 66.7)
30-day follow-up
Patients with evaluable results, n 29 23 52
Mean (SD) 4.1 (13.2) 8.7 (28.8) 6.1 (21.4)
Median (range) 0.0 (0.0, 50.0) 0.0 (0.0, 100.0) 0.0 (0.0, 100.0)
CE Carboplatin-etoposide, CTC Circulating tumor cell, CXCR4 Chemokine (C-X-C motif) receptor 4, IHC
Immunohistochemistry, N number of patients, n Number of patients in a category, SD Standard deviation
*P-value from 2-sample, 2-sided Mann-Whitney of null hypothesis that baseline values were same for treatment
arms
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AUC >0.5 (AUC = 0.702; CI = 0.577, 0.828;
P = 0.011) and a significant P < 0.05.
Kaplan-Meier survival estimates and Cox regression anal-
yses were done using optimum cutoffs of these 3 biomarkers,
comparing patients above and below the cutoffs in the overall
study population (Fig. 1a–j; Supplementary Table S5). The
analyses were conducted using the cutoffs at baseline and at
cycle 2, day 1 for both PFS and OS. Baseline tumor tissue
CXCR4 expression was not prognostic of either PFS or OS in
the overall study population. The Kaplan-Meier curves
Fig. 1 Kaplan-Meier curves for PFS and OS in the overall patient
population by biomarker levels a Baseline CXCR4 expression in tumor
tissue H-score ≥ 210 and <210 for PFS; b Baseline CXCR4 expression in
tumor tissue H-score ≥ 210 and <210 for OS; c Baseline CTC counts ≥6
and <6 for PFS; d Baseline CTC counts ≥6 and <6 for OS; e Cycle 2, day
1 CTC counts ≥6 and <6 for PFS; f Cycle 2, day 1 CTC counts ≥6 and <6
for OS; g Baseline %CXCR4+ CTCs ≥7% and <7% for PFS; h Baseline
%CXCR4+ CTCs ≥7% and <7% for OS; i Cycle 2, day 1 %CXCR4+
CTCs ≥7% and <7% for PFS; jCycle 2, day 1%CXCR4+ CTCs ≥7% and
<7% for OS
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(Fig. 1a, b) were not well separated for H-scores of ≥210
versus <210. CTCs ≥6 were prognostic of shorter PFS and
OS at baseline and at cycle 2, day 1: CTCs at baseline were
significant indicators for PFS (P = 0.024) and OS (P = 0.017),
and CTCs at cycle 2, day 1 were significant indicators for PFS
(P = 0.001) and OS (P = 0.001). Kaplan-Meier curves for PFS
and OSwere well separated for CTCs ≥6 versus <6 at baseline
(Fig. 1c, d) and cycle 2, day 1 (Fig. 1e, f). Baseline CXCR4+
CTCs ≥7% was prognostic of shorter PFS (P = 0.029) but not
OS (Supplementary Table S5; Fig. 1g, h). CXCR4+ CTCs
≥7% at cycle 2, day 1 was not prognostic of either PFS or
OS (Supplementary Table S5; Fig. 1i, j).
Predictive value of biomarker levels for PFS and OS
by treatment arm
The optimum cutoffs for the 3 biomarkers (H-score ≥ 210 for
CXCR4+ tumor tissue, CTCs ≥6, and CXCR4+ CTCs ≥7%)
Fig. 1 (continued)
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were applied to survival analyses by treatment arm. Kaplan-
Meier survival estimates (in months) and HR values for PFS
and OS at 4 and 6 months are shown by treatment arm in
Supplementary Table S4. All 3 biomarkers were analyzed at
baseline, and CTCs and %CXCR4+ CTCs at cycle 2, day 1.
None of the 3 biomarkers at their respective optimum cutoffs
was predictive of treatment response. Representative Kaplan-
Meier curves are shown in Fig. 2, including PFS for patients
with baseline CTCs ≥6 and PFS for patients with baseline
CXCR4+ CTCs ≥7%, by treatment arm (Fig. 2a, b). The
Kaplan-Meier curves were separated in the first 4 months of
treatment, but were no longer separated after approximately
4–5 months. Per study design, patients were on treatment for a
maximum of six 21-day cycles, which was approximately
4 months. An analysis was conducted for patients with both
baseline CTCs ≥6 and CXCR4+ CTCs ≥7%, considered a
higher-risk group, to evaluate whether a combined elevation
of these biomarkers may be predictive of treatment response
as measured as PFS and OS. Kaplan-Meier survival curves
and HR values show that this combination of elevated base-
line biomarkers was not predictive of PFS (Table 2; Fig. 2c) or
OS (data not shown).
Discussion
In a phase II study (NCT01439568 [22]) of LY2510924, a
cyclic peptide that blocks the binding of the ligand SDF-1
(CXCL12) to CXCR4 [16, 21], there was no difference in
median PFS for patients with ED-SCLC treated with
LY2510924 plus CE and CE [23]. We conducted post-hoc
exploratory analyses to evaluate the prognostic value of
CTC counts and CXCR4 expression in both CTCs and tumor
tissue in the overall study population, the predictive value of
these biomarkers for treatment response to LY2510924 plus
CE versus CE alone, and the correlation of CXCR4 expres-
sion in CTCs and tumors. These exploratory analyses were
done on a limited dataset with no adjustments for multiplicity,
and the results should be considered as hypotheses that need
further testing. The proportion of patients (83%) in our study
with ≥1 CTC/7.5 mL blood at baseline was similar to
Normanno et al. [26]. The median CTC count at baseline in
our study is comparable to reports in the literature for SCLC
(Hou et al. [8], Huang et al. [14], and Normanno et al. [26]).
The CELLSEARCH system has been used to detect CTCs
in various tumor types, including SCLC, making CTC counts
or characterization a useful biomarker to establish cutoffs [9,
12, 14]. In the present analyses using CELLSEARCH, an
optimum cutoff of ≥6 CTCs/7.5 mL blood at baseline and
post-treatment (cycle 2, day 1) was prognostic of shorter
PFS and OS. There were 77% and 36% of the patients in this
study with baseline and cycle 2, day 1 CTC counts ≥6, respec-
tively. Other studies have defined variable CTC cutoffs that
demonstrated prognostic value for treatment outcomes: 50
CTCs/7.5 mL by Hou et al. [9], 8 CTCs/7.5 mL by Naito et al.
[12], 2 CTCs/7.5 mL by both Hiltermann et al. [10] and Wu
et al. [27], 5 CTCs/7.5 mL by Cheng et al. [28], and 282
CTCs/7.5 mL by Normanno et al. [26]. In our analyses, a
cutoff of ≥6 CTCs was prognostic of both PFS and OS but
was not predictive of 4- or 6-month PFS for treatment with
Fig. 1 (continued)
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LY2510924 plus CE versus CE. To our knowledge, this was
the first analysis of CXCR4 expression in CTCs in SCLC, and
a comparison of CXCR4 expression in tumor and CTCs
(which may derive from the primary tumor or metastatic sites)
showed a weak positive correlation. CXCR4 baseline overex-
pression in tumor (≥210 H-score) was not prognostic of
shorter PFS or OS in patients with ED-SCLC. Baseline over-
expression of CXCR4 in CTCs (≥7% CXCR4+ CTCs) was
prognostic of shorter PFS, but not OS. Post-treatment (cycle 2,
day 1) overexpression of CXCR4 in CTCs (≥7% CXCR4+
CTCs) was not prognostic of PFS or OS.
In both treatment arms, we observed median CTC counts
and median %CXCR4+ CTCs decreases from baseline. Our
data showed that if CTCs are ≥6 at cycle 2, day 1 it is a very
strong prognostic biomarker of poor survival outcome (PFS
and OS). Our data are consistent with several reports showing
Fig. 2 Kaplan-Meier curves for PFS by treatment arm and biomarker
levels. a Baseline ≥6 CTCs; b Baseline ≥7% CXCR4+ CTCs; c Baseline
≥7% CXCR4+ CTCs and ≥6 CTCs. CE carboplatin-etoposide, CI
confidence interval, CTCs circulating tumor cells, CXCR4 chemokine
(C-X-C motif) receptor 4, HR hazard ratio at 4 months (end of
treatment), LY LY2510924, N number of patients, OS overall survival,
PFS progression-free survival
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that when CTCs are decreased in response to chemotherapy in
patients with SCLC, this can serve as a prognostic biomarker.
Naito et al. [12] showed that patients with post-treatment CTCs
≥8 had worse outcomes versus CTCs <8 (P = 0.0096); patients
with ≥8 CTCs at baseline also had a worse prognosis versus <8
CTCs at baseline (P = 0.0014). A study by Hou et al. [9] of
patients with SCLC treated with first-line chemotherapy report-
ed a decrease from pre-treatment CTC counts after 1 cycle of
chemotherapy, which was an independent prognostic factor,
and a higher number of CTCs were associated with shorter
OS and PFS. Similarly, Cheng et al. [28] reported that in
Chinese patients with ED-SCLC following 2 cycles of chemo-
therapy, ≥5 CTCs/7.5 mL decreases led to significantly shorter
median OS versus <5 CTCs/7.5 mL blood (P < 0.0124); mul-
tivariate analyses showed CTCswas an independent prognostic
marker for OS at baseline (P = 0.018) and after 2 cycles of
chemotherapy (P = 0.0249). Overall, CTC counts appear to
be a promising prognostic biomarker for ED-SCLC; collecting
CTCs from peripheral blood as a liquid biopsy, amenable to
repeat sampling, circumvents a need for invasive, inaccessible,
solid biopsies in this patient population.
CXCR4 is overexpressed in a variety of human cancers
including breast, lung, kidney, colon, ovarian, and brain
[29]. The landscape of clinical development of anti-CXCR4
therapies is emerging, and, at present, the prognostic role of
CXCR4 overexpression as a biomarker across different tu-
mors is unclear. This overexpression can correlate with in-
creased risk for recurrence and poor survival, depending on
tumor type and outcomes studied. Minamiya et al. [30] report-
ed that in patients with adenocarcinoma of the lung, higher
levels of tumor cell CXCR4 expression are prognostic of bet-
ter outcomes. In contrast, Li et al. [31] reported that CXCR4
co-expression with urokinase-type plasminogen activator re-
ceptor predicts worse prognosis of SCLC patients. In a meta-
analysis, the expression of CXCR4 was an independent prog-
nostic factor for lower survival and increased metastasis in
SCLC [32]. In our analysis, despite a weak positive correla-
tion between CXCR4+ tumor and CXCR4+ CTCs, CXCR4
overexpression in tumor was not a prognostic factor for sur-
vival outcomes. We analyzed CXCR4 expression in CTCs by
treatment arm, and Kaplan-Meier curves showed separation in
PFS between treatment arms through the 4-month course of
therapy, which did not reach statistical significance, for ≥6
CTCs or ≥7% CXCR4+ CTCs (Fig. 2a, b). This separation
was not observed at 6 months. Since no differences in clinical
endpoints were observed between treatment arms [23], data
from both arms were combined for a larger sample size to
evaluate biomarker prognostic value. This is a potential limi-
tation of the exploratory post-hoc analyses; a prospective
study is required to confirm CTC counts as prognostic of
outcomes. It is notable that the combined sample size of our
study (N = 89) is greater than those reported in several prior
studies: 38 patients in Hiltermann et al. [10], and 24 patients in
Naito et al. [12].
Our finding, that CXCR4 overexpression in tumors is not
prognostic of outcomes in SCLC, contrasts with several recent
meta-analyses of biomarker levels and lung cancer clinical
outcomes. Liang et al. [32] showed high-level CXCR4 tumor
expression (2037 patients) is related to poor prognosis in lung
cancer patients, and Zhao et al. [33] showed that CXCR4
overexpression (11,032 patients) predicts unfavorable OS in
lung cancer. Our analyses represent the first report we are
aware of measuring CXCR4 expression in both tumor and
CTCs, using the CELLSEARCH® platform. One previous
report from Reckamp et al. [34] showed that low co-
expression of CXCR4 and pan-cytokeratin in CTCs was prog-
nostic of improved OS in NSCLC, based on flow cytometry
analysis of peripheral blood from 16 patients; CXCR4 expres-
sion in NSCLC tumors was documented, but not further ana-
lyzed in addition to CTCs. Our observation, that elevated
baseline CXCR4 expression in CTCs (≥7% CXCR4+ CTCs)
is prognostic of worse PFS in ED-SCLC, whereas CXCR4
Table 2 Predictive value of
combined elevated baseline
markers for PFS (4 months or
6 months) by treatment arm
LY2510924 + CE
(N = 18)
CE
(N = 23)
Total
(N = 41)
Baseline ≥7% CXCR4+ CTCs and ≥6 CTC count
Kaplan-Meier estimate (mos)
Mean (SD) 5.3 (0.4) 4.9 (0.6) 5.0 (0.4)
Median (95% CI) 5.5 (3.9, 6.1) 4.8 (2.9, 6.2) 4.9 (3.9, 6.1)
HR LY2510924 + CE vs CE (95% CI) 0.94 (0.46, 1.95)
P-value* 0.872
HR LY2510924 + CE vs CE (95% CI) 4 mos 0.49 (0.15, 1.59)
P-value through 4 mos* 0.223
HR LY2510924 + CE vs CE (95% CI) 6 mos 0.79 (0.34, 1.85)
P-value through 6 mos* 0.588
CE Carboplatin-etoposide, CI Confidence interval, CTCs Circulating tumor cell, HR Hazard ratio, mosMonths
*P-value from a log-rank test
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overexpression in tumor is not, has several possible explana-
tions beyond study design. CTCs may better represent the
cells shed by primary and metastatic tumors versus tumor
tissue biopsied from a single site. CTC samples drawn imme-
diately prior to start of the study may better represent disease
status versus tumor biopsy that may have been obtained less
proximal to start of the study. Additional prospective study is
required for confirmation and clarity on CXCR4+ CTCs as a
prognostic biomarker. Lastly, several isoforms of CXCR4
have been identified in cancer cell lines, including alternate
splice variants [35, 36]. Our study did not differentiate be-
tween isoforms of CXCR4 detected in biopsied tumor and
blood CTCs, the clinical relevance of which is not known.
In summary, positive CXCR4 expression in tumor tissue
was not significantly prognostic of survival in 89 patients with
ED-SCLC in the present analysis. Neither baseline CTC
counts or CXCR4 expression in tumor tissue or CTCs were
predictive of treatment response for CXCR4 peptide antago-
nist LY2510924 plus CE versus CE alone. However, in gen-
eral, CTC enumeration and CXCR4 expression in CTCs are
promising prognostic biomarkers for ED-SCLC at baseline
and post-treatment, as evidenced in the literature. The feasi-
bility of conducting biomarker, prognostic, and predictive
analyses in future SCLC studies is facilitated by peripheral
blood CTC collection as a liquid biopsy, which has the poten-
tial to replace technically difficult solid biopsies in this patient
population.
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